Doxycycline
doxycycline hyclate / monohydrate — brands include Vibramycin, Doryx, Oracea, Monodox, Acticlate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Rickettsial infections (RMSF, typhus, Q fever) | All ages | First-line | FDA Approved |
| Chlamydial infections (urethritis, cervicitis, LGV, trachoma, psittacosis) | Adults | First-line or alternative | FDA Approved |
| Respiratory tract infections (CAP with atypical pathogens, AECB) | Adults and pediatrics >8 y | Monotherapy or combination | FDA Approved |
| Early Lyme disease (erythema migrans) | Adults and children ≥8 y (≥45 kg) | First-line | FDA Approved |
| Sexually transmitted infections (syphilis, chancroid, granuloma inguinale, NGU) | Adults | First-line or alternative | FDA Approved |
| Malaria prophylaxis (P. falciparum) | Adults and children >8 y | Monotherapy prophylaxis | FDA Approved |
| Anthrax (inhalational, post-exposure) | All ages (including <8 y) | First-line | FDA Approved |
| Severe acne (adjunctive therapy) | Adults and adolescents | Adjunctive | FDA Approved |
| Plague, tularemia, cholera, brucellosis | Adults and pediatrics | First-line or combination | FDA Approved |
Doxycycline is one of the most versatile antibiotics in clinical practice, combining broad-spectrum activity against gram-positive and gram-negative bacteria, atypical organisms, spirochaetes, rickettsiae, and certain protozoa. Its favourable pharmacokinetic profile — near-complete oral absorption, long half-life enabling once- or twice-daily dosing, and no need for renal dose adjustment — has made it a workhorse antibiotic across infectious disease, dermatology, and travel medicine. The CDC also recommends doxycycline as post-exposure prophylaxis for bacterial STIs (doxyPEP) in certain populations.
Doxycycline post-exposure prophylaxis (doxyPEP) for bacterial STIs: 200 mg within 24–72 hours after condomless sex in MSM/TGW. Supported by CDC guidelines (2024). Evidence quality: High.
Rosacea (sub-antimicrobial dose): 40 mg modified-release once daily (Oracea). FDA-approved for this indication under a separate label. Evidence quality: High.
Pleural effusion sclerotherapy: Instilled intrapleurally as a chemical pleurodesis agent. Evidence quality: Moderate.
Periodontitis (sub-antimicrobial dose): 20 mg twice daily as adjunct to scaling and root planing (Periostat). FDA-approved under separate label. Evidence quality: High.
MRSA skin infections: Used as alternative oral therapy for mild, non-purulent skin and soft tissue infections when susceptible. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| General infections (mild-moderate) | 200 mg day 1 (100 mg q12h) | 100 mg daily | 100 mg q12h | Can give maintenance as 50 mg q12h or 100 mg once daily (FDA PI) Severe infections: 100 mg q12h throughout |
| Early Lyme disease (erythema migrans) | 100 mg q12h | 100 mg q12h | 100 mg q12h | 10–21 days depending on clinical response (IDSA 2021) |
| Chlamydia (uncomplicated urogenital) | 100 mg q12h | 100 mg q12h | 100 mg q12h | 7 days (CDC 2021) |
| Primary and secondary syphilis (penicillin-allergic) | 100 mg q12h | 100 mg q12h | 100 mg q12h | 14 days (CDC 2021); some guidelines suggest 28 days for late latent Not for neurosyphilis or pregnancy |
| Community-acquired pneumonia (atypical cover) | 100 mg q12h | 100 mg q12h | 100 mg q12h | 5–7 days; often combined with beta-lactam for moderate-severe CAP (ATS/IDSA) |
| Malaria prophylaxis | 100 mg daily | 100 mg daily | 100 mg daily | Start 1–2 days before travel; continue for 4 weeks after leaving endemic area (FDA PI) |
| RMSF / rickettsial infection | 100 mg q12h | 100 mg q12h | 100 mg q12h | Treat for ≥3 days after defervescence and clinical improvement; minimum 5–7 days (CDC) |
| Anthrax, post-exposure prophylaxis | 100 mg q12h | 100 mg q12h | 100 mg q12h | 60 days (FDA PI) |
| Acne vulgaris (moderate-severe) | 50–100 mg daily | 50–100 mg daily | 100 mg q12h | Typically 3–4 months; combine with topical retinoid; taper when possible |
| DoxyPEP for bacterial STIs (MSM/TGW) | 200 mg single dose | Event-driven | 200 mg per event (max q24h) | Within 24 h (up to 72 h) of condomless sex (CDC 2024) Not currently recommended for cisgender women |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| General infections (>8 y, ≤45 kg) | 4.4 mg/kg/day div q12h (day 1) | 2.2 mg/kg/day | 4.4 mg/kg/day | Severe infections: 4.4 mg/kg/day throughout. Children >45 kg use adult dose. |
| RMSF / rickettsial (any age) | 2.2 mg/kg q12h | 2.2 mg/kg q12h | 100 mg q12h | First-line at any age — tooth staining risk does not outweigh mortality risk from untreated RMSF (CDC/AAP) |
| Anthrax post-exposure (<45 kg) | 2.2 mg/kg q12h | 2.2 mg/kg q12h | 100 mg q12h | 60 days (FDA PI); ≥45 kg use adult dose |
| Malaria prophylaxis (>8 y) | 2 mg/kg daily | 2 mg/kg daily | 100 mg daily | Start 1–2 days before travel; continue 4 weeks after |
Unlike most antibiotics, doxycycline does not accumulate in renal failure because it is eliminated via dual routes — approximately 40% renal and the remainder through faecal excretion via the gut. Studies confirm no significant change in serum half-life even in patients with severe renal impairment (CrCl <10 mL/min), and haemodialysis does not alter serum levels. This makes doxycycline one of the few antibiotics safely used at full dose in dialysis patients.
Pharmacology
Mechanism of Action
Doxycycline is a bacteriostatic agent that reversibly binds to the 30S ribosomal subunit of susceptible bacteria, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This prevents new amino acids from being added to the growing peptide chain, effectively halting protein synthesis without immediately killing the organism. Bacterial selectivity arises because doxycycline enters bacterial cells through energy-dependent active transport systems that are absent in mammalian cells, resulting in intracellular concentrations high enough to inhibit the bacterial ribosome but too low to significantly impair mitochondrial protein synthesis in host cells. Beyond its antimicrobial activity, doxycycline inhibits matrix metalloproteinases (MMPs), suppresses neutrophil chemotaxis and inflammatory cytokine production, and blocks angiogenesis — properties exploited therapeutically in rosacea, periodontitis, and emerging research in aortic aneurysm stabilisation. In malaria, doxycycline targets the apicoplast ribosome of Plasmodium falciparum, disrupting parasite fatty acid synthesis and heme biosynthesis.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~93% bioavailable (oral); Tmax 1.5–4 h; food reduces Cmax by ~20% but does not clinically impair absorption; dairy has only modest effect unlike older tetracyclines | Can be given with food to reduce GI upset without meaningful loss of efficacy; avoid concurrent divalent/trivalent cation antacids, iron, or calcium supplements |
| Distribution | Vd 0.7–1.4 L/kg; protein binding 82–93%; high concentrations in lung, liver, kidney, bone, and gallbladder; low CSF penetration | Excellent tissue penetration for respiratory, genital, and tick-borne infections; poor CNS penetration limits utility for meningitis; concentrates in bone (chelates calcium) |
| Metabolism | No major metabolites identified; negligible hepatic biotransformation; enzyme inducers (barbiturates, carbamazepine, phenytoin) decrease half-life | Minimal drug-drug interactions via CYP450; however, CYP inducers accelerate elimination and may reduce efficacy — consider dose increase or alternative |
| Elimination | t½ 12–25 h (mean ~18 h); ~40% excreted renally as unchanged drug, remainder via faecal route; haemodialysis does not alter serum half-life | Once- or twice-daily dosing supported by long half-life; no dose adjustment in renal or hepatic impairment — a unique advantage over most antibiotics |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 10–33% | Dose-related and most common complaint. Substantially reduced by taking with food. Lower with delayed-release formulations (Doryx). |
| Photosensitivity | 7–21% | Phototoxic reaction (not photoallergic). Dose- and UV-exposure dependent. Counsel all patients on sun protection. More common than with other tetracyclines. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea | 6–8% | Usually mild. Consider C. difficile if persistent or bloody. |
| Vomiting | 4–8% | More common when taken on an empty stomach or with inadequate fluid |
| Abdominal pain / dyspepsia | 5–10% | Taking with a full glass of water and food minimises risk; avoid lying down within 30 minutes of dosing |
| Headache | 3–5% | Usually self-limiting. Distinguish from early intracranial hypertension if persistent or associated with visual symptoms. |
| Vaginal candidiasis | 3–6% | More common with prolonged courses (>2 weeks). Advise patients and consider prophylactic antifungal. |
| Rash (non-serious) | 1–3% | Maculopapular most common. Discontinue and evaluate if severe or associated with systemic symptoms. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Esophageal ulceration / erosion | Uncommon | Days; often after bedtime dosing with insufficient water | Discontinue; counsel to take with full glass of water and remain upright for ≥30 min. Delayed-release formulation may prevent recurrence. |
| Intracranial hypertension (pseudotumor cerebri) | Rare | Days to weeks | Discontinue doxycycline immediately. Ophthalmology referral for fundoscopy. Do not co-administer with isotretinoin (additive risk). |
| Clostridioides difficile-associated diarrhea | Uncommon | During or up to 2 months after therapy | Stool C. difficile toxin assay; discontinue doxycycline; initiate oral vancomycin or fidaxomicin |
| Severe cutaneous reactions (SJS/TEN, DRESS) | Very rare | 1–4 weeks | Permanent discontinuation; emergency dermatology referral; do not re-challenge |
| Hepatotoxicity | Rare | Variable; more likely with high IV doses or pregnancy | Discontinue; monitor LFTs. Fatty liver of pregnancy associated with IV tetracycline use is a class effect. |
| Tooth discoloration (yellow-grey-brown) | Common if used in children <8 y during tooth development | During prolonged or repeated courses in developing teeth | Avoid in children <8 y unless no alternative (anthrax, RMSF). Short courses (≤21 days) in children <8 y associated with minimal staining risk per AAP. |
| Skeletal effects (inhibition of bone growth) | Dose-dependent in young children | During treatment | Reversible on discontinuation. Risk applies primarily to prolonged courses in growing children. |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| GI intolerance (nausea, vomiting) | ~3–5% | Most common single reason; reduced with food co-administration and delayed-release formulations |
| Photosensitivity | ~2–3% | More problematic in tropical settings (malaria prophylaxis) and summer months |
| Rash | ~1–2% | Requires clinical assessment to exclude serious cutaneous reaction |
Esophageal ulceration is the most preventable serious adverse effect of doxycycline. Counsel every patient to take the capsule or tablet with a full glass (240 mL) of water, remain upright for at least 30 minutes after dosing, and avoid taking the medication immediately before bedtime. If a patient has difficulty swallowing capsules or has a history of esophageal stricture, the delayed-release tablet (Doryx) or oral suspension should be prescribed instead.
Drug Interactions
Unlike macrolides, doxycycline has minimal CYP450 interaction potential because it undergoes negligible hepatic metabolism. Its primary drug interactions involve chelation with polyvalent cations reducing absorption, induction of its elimination by hepatic enzyme inducers, and pharmacodynamic antagonism with bactericidal antibiotics.
Monitoring
-
Clinical Response
48–72 h after initiation
Routine Assess for clinical improvement. If no improvement, reconsider diagnosis, obtain cultures, and broaden coverage as needed. -
Hepatic Function
Baseline for long-term therapy; during if symptoms arise
Trigger-based LFTs if jaundice, abdominal pain, or dark urine develop. Particularly important for patients receiving high-dose IV therapy or those with pre-existing liver disease. -
Renal Function (BUN)
Long-term therapy
Routine Tetracyclines have anti-anabolic effects that may increase BUN. Doxycycline has less effect on BUN than older tetracyclines at standard doses, but monitor in patients with pre-existing renal impairment on prolonged courses. -
INR (if on warfarin)
Within 3–5 days of starting
Trigger-based Doxycycline may enhance anticoagulant effect. Re-check INR early in course and adjust warfarin as indicated. -
Skin Assessment
Ongoing during therapy
Routine Monitor for photosensitivity reactions, especially in patients with significant sun exposure. Advise sunscreen (broad-spectrum UVA/UVB) and protective clothing. -
Visual Symptoms
As needed
Trigger-based New headache, blurred vision, diplopia, or visual field loss may indicate intracranial hypertension. Discontinue doxycycline and arrange urgent ophthalmology assessment if suspected. -
Syphilis Serology
Monthly for 4 months after treatment
Routine When doxycycline is used for syphilis in penicillin-allergic patients, perform dark-field examination before treatment and repeat serology monthly to confirm response (FDA PI).
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to doxycycline or any tetracycline-class antibiotic
Relative Contraindications (Specialist Input Recommended)
- Pregnancy (2nd and 3rd trimester): Permanent tooth discoloration and inhibition of bone growth in the fetus. Use only if no safer alternative exists and maternal benefit clearly outweighs fetal risk.
- Children under 8 years of age: Risk of permanent tooth discoloration with repeated or prolonged courses. Exceptions: anthrax, RMSF, and other life-threatening infections where doxycycline is first-line regardless of age (AAP/CDC).
- Concurrent isotretinoin therapy: Additive risk of pseudotumor cerebri. Separate courses temporally.
- Myasthenia gravis: Rare reports of neuromuscular blockade with tetracyclines.
Use with Caution
- Esophageal disease or dysphagia: Increased risk of esophageal ulceration. Use liquid formulation or delayed-release tablets.
- Significant sun exposure: Photosensitivity risk requires proactive counselling on UV protection.
- Severe hepatic impairment: No formal dose adjustment, but hepatotoxicity is a tetracycline class effect — use with care and monitor LFTs.
- Patients on enzyme inducers (barbiturates, carbamazepine, phenytoin): Doxycycline half-life decreased. Consider dose escalation or alternative.
- Lactation: Short courses (≤21 days) likely carry minimal risk; prolonged therapy should be avoided.
The use of tetracycline-class drugs, including doxycycline, during tooth development (last half of pregnancy, infancy, and childhood to age 8 years) may cause permanent discoloration of the teeth (yellow-grey-brown). This adverse reaction is more common with long-term use but has been observed after repeated short courses. Enamel hypoplasia has also been reported. Tetracyclines form a stable calcium complex in bone-forming tissue, and a decrease in fibula growth rate has been documented in premature infants given oral tetracycline. These effects are considered reversible on discontinuation of the drug.
Patient Counselling
Purpose of Therapy
Doxycycline is an antibiotic that stops bacteria from growing by blocking their ability to make essential proteins. It is used for a wide range of infections including respiratory infections, Lyme disease, sexually transmitted infections, acne, and malaria prevention. Complete the full course as prescribed, even if symptoms improve early, to prevent the infection from returning or becoming resistant to treatment.
How to Take
Take doxycycline with a full glass of water (at least 240 mL) and remain upright for at least 30 minutes afterward. It can be taken with food to reduce stomach upset — unlike older tetracyclines, food has only a minor effect on doxycycline absorption. However, avoid taking it at the same time as antacids, iron supplements, calcium, or multivitamins containing minerals, as these can prevent the medication from working properly. If you take these products, space them at least 2–3 hours apart from doxycycline.
Sources
- Doxycycline Capsules USP — Full Prescribing Information. Revised 02/2018. drugs.com/pro/doxycycline Primary source for approved indications, dosing, adverse reactions, drug interactions, and contraindications.
- DORYX MPC (doxycycline hyclate delayed-release tablets) — FDA-approved labeling. Revised 2020. accessdata.fda.gov Delayed-release formulation label with specific dosing for malaria prophylaxis, STIs, anthrax, and rickettsial infections.
- LYMEPAK (doxycycline hyclate) — FDA-approved labeling for early Lyme disease. Revised 3/2025. accessdata.fda.gov First doxycycline product with a specific Lyme disease indication; provides focused safety data for this population.
- Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296-1306. doi:10.1056/NEJMoa2211934 The DoxyPEP trial — pivotal RCT demonstrating 66% reduction in STIs in MSM/TGW with event-driven doxycycline 200 mg post-exposure.
- Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308-317. doi:10.1016/S1473-3099(17)30725-9 First RCT substudy showing doxycycline PEP reduces syphilis and chlamydia incidence in MSM by ~70%.
- Chan PA, Le Brazidec DL, Becasen JS, et al. Safety of longer-term doxycycline use: a systematic review and meta-analysis with implications for bacterial STI chemoprophylaxis. Sex Transm Dis. 2023;50(11):701-712. doi:10.1097/OLQ.0000000000001865 CDC-affiliated systematic review of 67 studies on doxycycline ≥8 weeks confirming GI and dermatological AEs as the most common reasons for discontinuation.
- CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial STI Prevention. MMWR. 2024;73(RR-2):1-8. cdc.gov/mmwr CDC guideline establishing doxyPEP as standard of care for MSM/TGW at high risk of bacterial STIs.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(RR-4):1-187. doi:10.15585/mmwr.rr7004a1 Current CDC STI treatment guidelines specifying doxycycline dosing for chlamydia, syphilis, LGV, and epididymitis.
- Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for Prevention, Diagnosis, and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):e1-e48. doi:10.1093/cid/ciaa1215 IDSA guideline confirming doxycycline 100 mg BID x 10–21 days as first-line for early Lyme disease.
- Holmes NE, Charles PGP. Safety and efficacy review of doxycycline. Clin Med Ther. 2009;1:CMT.S2035. doi:10.4137/CMT.S2035 Comprehensive review covering pharmacokinetics, mechanism of action, resistance, and safety profile of doxycycline.
- Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329-1342. doi:10.1016/j.clinthera.2005.09.005 Systematic comparison of adverse event profiles between doxycycline and minocycline from 24 clinical trials.
- Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15(6):355-366. doi:10.2165/00003088-198815060-00001 Foundational PK review establishing doxycycline’s bioavailability, protein binding, dual elimination, and lack of accumulation in renal impairment.
- Thompson EJ, Wu H, Melloni C, et al. Population pharmacokinetics of doxycycline in children. Antimicrob Agents Chemother. 2019;63(12):e01508-19. doi:10.1128/AAC.01508-19 Population PK model demonstrating comparable clearance and volume of distribution in children vs adults; supports weight-based dosing in pediatrics.